Remdesivir is widely considered to be a front-runner among the investigational therapies being tested as treatments for COVID-19 Gilead Sciences Inc. (GILD) said that its experimental COVID-19 therapy remdesivir met the main goal in a government-funded clinical trial and that a shorter dosing regimen was as successful as a longer one in a separate study. The early findings set the stage for the closely watched drug to move toward a possible emergency use authorization or approval from the U.S. Food and Drug Administration. The drug is currently being used on an expanded use or compassionate use basis. Shares of Gilead...